Bristol-Myers Squibb Company http://www.alacrastore.com/company-snapshot/Bristol_Myers_Squibb_Company-1002495 25 Nov 2009 10:00:19 EST 1002495 Bristol-Myers Squibb Company en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/research/moodys-global-credit-research-Bristol_Myers_s_Plan_to_Shed_Mead_Johnson_Is_a_Credit_Positive_in_the_Short_Term_But_Strategy_Contrasts_With_Peers-PBC_121339PBC_121339moodys/PBC_121339pdf23 Nov 2009 08:23:26 ESTpdfBristol-Myers Squibb CompanyBristol-Myers Squibb Company115000115000150.000023 Nov 2009NewsIssuer CommentC...November #### Issuer Comment Moody's Corporate Finance ­ Bristol-Myers's Plan to Shed Mead Johnson Is a Credit-Positive in the Short Term, But Strategy Contrasts With Peers... 11500018281829545600045912621656711000711400711700UNITED STATESINDUSTRIAL115000Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39782394BW-0001-39782394newstex/BW-0001-39782394xmlNewstex Inc.2005Apollo Global, Inc.Newstex Inc.newstex.comnewstexBW-0001-39782394Business Wire0001Business WireBW1Newstex Inc.Business Wire04000000040060000400600104016000040160130401600117 Nov 2009 08:22:36 EST1800000018007000180150001900000019003000190020001900201319002004190020071900201511/17/2009 Nov. ##, #### (Business Wire) -- Apollo Global, a majority-owned subsidiary of Apollo Group, Inc. (NASDAQ: APOL) today announced the following executive appointments effective immediately: John Baule has joined Apollo Global as Chief...APOLLO GROUP INCBRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEK12 INCJohn F BauleAPOLBMYBMY PRLRNNewsNewstexUS - Bristol-Myers Squibb Co (Bristol-Myers) planned an exchange offer for which it was to split off its ##.##% interest, or ### mil common shares of Mead Johnson Nutrition Co (Mead Johnson), an Evansville-based producer and wholesaler of infant and child nutrition products, in a transaction valued at USD #. ### bil. Bristol offered to exchange # common share per #. #### Mead Johnson common shares. The shares were valued based on Bristol- Myers's closing stock price of USD ##.## on ## November ####, the last full trading day prior to announcement.17 Nov 2009 08:20:43 EST110122110122110122110122Bristol-Myers Squibb CoBristol-Myers Squibb CoBristol-Myers Squibb CoBristol-Myers Squibb Cohttp://www.alacrastore.com/storecontent/Thomson_M%26A/Bristol_Myers_Squibb_Co_exchanges_equity_for_debt-2127876020sdc/21278760202127876020Copyright © 2009, Thomson Financial, All Rights ReservedNew YorkDrugsUnited StatesPharmaceutical preparations2834NYNew YorkPublicBMY2023:Dry, condensed, and evaporated dairy products2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2842:Specialty cleaning and polishing preparations2844:Perfumes, cosmetics, and other toilet preparations3634:Electric housewares and fans3841:Surgical and medical instruments and apparatus3842:Orthopedic, prosthetic, and surgical supplies8731:Commercial physical and biological research2023:Dry, condensed, and evaporated dairy products2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2842:Specialty cleaning and polishing preparations2844:Perfumes, cosmetics, and other toilet preparations3634:Electric housewares and fans3841:Surgical and medical instruments and apparatus3842:Orthopedic, prosthetic, and surgical supplies8731:Commercial physical and biological researchCravath, Swaine & MooreNew YorkDrugsUnited StatesPharmaceutical preparations2834NYNew YorkPublicBMY7579002Mnfr pharm,med prodMnfr pharm,med prodCommon StockCommon Stock7579002Nov 17 20090.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.00000Bristol-Myers Squibb Co,located in New York, New York,manufactures pharmaceuticals,medical devices, healthproducts, surgical suppliesand equipment, in vitro and invitro diagnostic substances,toiletries, beauty aids,household products, and dry,condensed and evaporated dairyproducts. The company'sblockbuster cardiovascularline-up includes heart diseasedrug Plavix, as well asPravachol (which lowerscholesterol) and Avapro (forhypertension). BMS also makesantipsychotic medicationAbilify and drugs in a numberof other therapeuticcategories, particularlyoncology, virology (includingHIV), and autoimmune disease.The company was founded in1877.Bristol-Myers Squibb Co, located in New York, New York,manufactures pharmaceuticals, medical devices, healthproducts, surgical supplies and equipment, in vitro and invitro diagnostic substances, toiletries, beauty aids,household products, and dry, condensed and evaporated dairyproducts. The company's blockbuster cardiovascular line-upincludes heart disease drug Plavix, as well as Pravachol(which lowers cholesterol) and Avapro (for hypertension).BMS also makes antipsychotic medication Abilify and drugs ina number of other therapeutic categories, particularlyoncology, virology (including HIV), and autoimmune disease.The company was founded in 1877.Bristol-Myers Squibb Co, located in New York, New York, manufactures pharmaceuticals, medical devices, health products, surgical supplies and equipment, in vitro and in vitro diagnostic substances, toiletries, beauty aids, household products, and dry, condensed and evaporated dairy products. The company's blockbuster cardiovascular line-up includes heart disease drug Plavix, as well as Pravachol (which lowers cholesterol) and Avapro (for hypertension). BMS also makes antipsychotic medication Abilify and drugs in a number of other therapeutic categories, particularly oncology, virology (including HIV), and autoimmune disease. The company was founded in 1877.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.00000Bristol-Myers Squibb Co,located in New York, New York,manufactures pharmaceuticals,medical devices, healthproducts, surgical suppliesand equipment, in vitro and invitro diagnostic substances,toiletries, beauty aids,household products, and dry,condensed and evaporated dairyproducts. The company'sblockbuster cardiovascularline-up includes heart diseasedrug Plavix, as well asPravachol (which lowerscholesterol) and Avapro (forhypertension). BMS also makesantipsychotic medicationAbilify and drugs in a numberof other therapeuticcategories, particularlyoncology, virology (includingHIV), and autoimmune disease.The company was founded in1877.Bristol-Myers Squibb Co, located in New York, New York,manufactures pharmaceuticals, medical devices, healthproducts, surgical supplies and equipment, in vitro and invitro diagnostic substances, toiletries, beauty aids,household products, and dry, condensed and evaporated dairyproducts. The company's blockbuster cardiovascular line-upincludes heart disease drug Plavix, as well as Pravachol(which lowers cholesterol) and Avapro (for hypertension).BMS also makes antipsychotic medication Abilify and drugs ina number of other therapeutic categories, particularlyoncology, virology (including HIV), and autoimmune disease.The company was founded in 1877.Bristol-Myers Squibb Co, located in New York, New York, manufactures pharmaceuticals, medical devices, health products, surgical supplies and equipment, in vitro and in vitro diagnostic substances, toiletries, beauty aids, household products, and dry, condensed and evaporated dairy products. The company's blockbuster cardiovascular line-up includes heart disease drug Plavix, as well as Pravachol (which lowers cholesterol) and Avapro (for hypertension). BMS also makes antipsychotic medication Abilify and drugs in a number of other therapeutic categories, particularly oncology, virology (including HIV), and autoimmune disease. The company was founded in 1877.0.000000.000000.000001980.98000NU.S. Dollar16 Nov 09Mon, 16 Nov 2009 00:00:00 ESTDate Announced: 11/16/2009Date Effective:Exchange OfferNot Appl.0.000000.000000.000000.000000.0000023.18000Price/Share0.000006538.24 U.S. Dollar6538.2450045919.120006538.24 U.S. Dollar6538.245000.000000.0000023.1800023.180006538.245006538.24 U.S. Dollar1.00000N3887.416000.000000.000000.000000.000000.000006538.245006538.245000.000000.000000.000000.000000.000000.000000.000000.0000014.239000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.00000US - Bristol-Myers Squibb Co(Bristol-Myers) planned anexchange offer for which itwas to split off its 83.13%interest, or 170 mil commonshares of Mead JohnsonNutrition Co (Mead Johnson),an Evansville-based producerand wholesaler of infant andchild nutrition products, ina transaction valued at USD 6.538 bil. Bristol offered toexchange 1 common share per 0.6027 Mead Johnson commonshares. The shares werevalued based on Bristol-Myers's closing stock priceof USD 23.18 on 13 November2009, the last full tradingday prior to announcement.US - Bristol-Myers Squibb Co (Bristol-Myers) planned an exchange offer for which it was to split off its 83.13% interest, or 170 mil common shares of Mead Johnson Nutrition Co (Mead Johnson), an Evansville-based producer and wholesaler of infant and child nutrition products, in a transaction valued at USD 6. 538 bil. Bristol offered to exchange 1 common share per 0. 6027 Mead Johnson common shares. The shares were valued based on Bristol- Myers's closing stock price of USD 23.18 on 13 November 2009, the last full trading day prior to announcement.US - Bristol-Myers Squibb Co (Bristol-Myers) planned an exchange offer for which it was tosplit off its 83.13% interest, or 170 mil common shares of Mead Johnson Nutrition Co (MeadJohnson), an Evansville-based producer and wholesaler of infant and child nutritionproducts, in a transaction valued at USD 6. 538 bil. Bristol offered to exchange 1 commonshare per 0. 6027 Mead Johnson common shares. The shares were valued based on Bristol-Myers's closing stock price of USD 23.18 on 13 November 2009, the last full trading dayprior to announcement.US - Bristol-Myers Squibb Co (Bristol-Myers) planned an exchange offer for which it was to split off its 83.13% interest, or 170 mil common shares of Mead Johnson Nutrition Co (Mead Johnson), anEvansville-based producer and wholesaler of infant and child nutrition products, in a transaction valued at USD 6. 538 bil. Bristol offered to exchange 1 common share per 0. 6027 Mead Johnson commonshares. The shares were valued based on Bristol- Myers's closing stock price of USD 23.18 on 13 November 2009, the last full trading day prior to announcement.US - Bristol-Myers Squibb Co (Bristol-Myers) planned an exchange offer for which it was to split off its 83.13% interest, or 170 milcommon shares of Mead Johnson Nutrition Co (Mead Johnson), an Evansville-based producer and wholesaler of infant and child nutritionproducts, in a transaction valued at USD 6. 538 bil. Bristol offered to exchange 1 common share per 0. 6027 Mead Johnson common shares.The shares were valued based on Bristol- Myers's closing stock price of USD 23.18 on 13 November 2009, the last full trading day prior toannouncement.0.000000.000000.00000CitiGoldman Sachs & CoMorgan Stanley1.000002.000003.00000Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002023:Dry, condensed, and evaporated dairy products2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2842:Specialty cleaning and polishing preparations2844:Perfumes, cosmetics, and other toilet preparations3634:Electric housewares and fans3841:Surgical and medical instruments and apparatus3842:Orthopedic, prosthetic, and surgical supplies8731:Commercial physical and biological research7579002New YorkUnited States2834New YorkPublicBMY2023:Dry, condensed, and evaporated dairy products2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2835:In vitro and in vivo diagnostic substances2836:Biological products, except diagnostic substances2842:Specialty cleaning and polishing preparations2844:Perfumes, cosmetics, and other toilet preparations3634:Electric housewares and fans3841:Surgical and medical instruments and apparatus3842:Orthopedic, prosthetic, and surgical supplies8731:Commercial physical and biological research7579002New YorkUnited States2834New YorkPublicBMY6538.245006538.245006538.245003887.41600Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/research/moodys-global-credit-research-Moody_s_says_Bristol_s_split_off_of_MJ_does_not_impact_A2_rating-PR_190435_115000PR_190435_115000moodys/PR_190435_115000html17 Nov 2009 02:36:16 ESThtmlBristol-Myers Squibb CompanyBristol-Myers Squibb Company115000115000150.000016 Nov 2009NewsAnnouncementCGlobal Credit Research Announcement ## NOV #### Announcement: Bristol-Myers Squibb Company Moody's says Bristol's split-off of MJ does not impact A# rating New York, November ##, #### -- Moody's Investors Service commented that the...11500018281829545600045912621656711000711400711700UNITED STATESINDUSTRIAL115000Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/research/moodys-global-credit-research-Moody_s_says_Bristol_s_split_off_of_MJ_does_not_impact_A2_rating-CMT_0000515237CMT_0000515237moodys/CMT_0000515237html17 Nov 2009 02:35:58 ESThtmlBristol-Myers Squibb CompanyBristol-Myers Squibb Company115000115000150.000016 Nov 2009NewsIssuer CommentCGlobal Credit Research Issuer Comment ## NOV #### Issuer Comment: Bristol-Myers Squibb Company Moody's says Bristol's split-off of MJ does not impact A# rating Moody's Investors Service commented that the announcement by Bristol-Myers...11500018281829545600045912621656711000711400711700UNITED STATESINDUSTRIAL115000Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/research/fitch-ratings-Fitch_Bristol_Myers_Squibb_s_Ratings_Unlikely_to_be_Affected_by_Mead_Johnson_Spin_off-535976_pr_frame535976_pr_framefitch/535976_pr_framehtmlBristol-Myers Squibb Company8036141916 Nov 2009 02:38:00 EST0103170085Press ReleaseBMYFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.ARGDEUESPGBRINDMEXRUSUSA010100000101010001020000010300000103100001031700020200000300000003010000030108000302000003030000040000000401000004020000Credit & Investment ResearchFitch Researchhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39761544BW-0001-39761544newstex/BW-0001-39761544xmlNewstex Inc.2005Fitch RatingsNewstex Inc.newstex.comnewstexBW-0001-39761544Business Wire0001Business WireBW1Newstex Inc.Business Wire040000000401800004016000040090000400900102000000020020000200200816 Nov 2009 01:22:14 EST1800000018009000180240001801800011/16/2009 Nov. ##, #### (Business Wire) -- Fitch Ratings does not expect Bristol-Myers Squibb Co.'s (Bristol-Myers Squibb) announced spin-off of its remaining ownership in Mead Johnson Nutrition Co. (Mead Johnson) to have a material impact on...BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEMEAD JOHNSON NUTRITION COBMYBMY PRMJNNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B2552935B2552935ccbn/B2552935norm16 Nov 2009 11:08:00 EST2552935Edited Brief of BMY conference call or presentation, 16-Nov-09 8:30am ETBristol-Myers Squibb106.0000EditedBristol-Myers Squibb Conference Call on the Mead Johnson Split-Off SummaryBMY8:30am ETBrief...David Risinger Morgan Stanley - Analyst Jami Rubin Goldman Sachs - Analyst Catherine Arnold Credit Suisse - Analyst John Boris Citi - Analyst... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2552935T2552935ccbn/T2552935norm16 Nov 2009 10:06:13 EST2552935Final Transcript of BMY conference call or presentation, 16-Nov-09 8:30am ETBristol-Myers Squibb106.0000FinalBristol-Myers Squibb Conference Call on the Mead Johnson Split-Off TranscriptBMY8:30am ETTranscript...David Risinger Morgan Stanley - Analyst Jami Rubin Goldman Sachs - Analyst Catherine Arnold Credit Suisse - Analyst John Boris Citi - Analyst... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-39736780BW-0001-39736780newstex/BW-0001-39736780xmlNewstex Inc.2005Bristol-Myers Squibb CompanyNewstex Inc.newstex.comnewstexBW-0001-39736780Business Wire0001Business WireBW1Newstex Inc.Business Wire040000000401600004016019040160470401600315 Nov 2009 07:22:59 EST18000000180130001801200018025000180040001900000019001000190010351900103211/15/2009 Nov. ##, #### (Business Wire) -- Bristol-Myers Squibb Company (NYSE: BMY) today announced it will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off to be a tax-advantaged way to further deliver...BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEMEAD JOHNSON NUTRITION COJAMES M CORNELIUSBMYBMY PRMJNNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39586213BW-0001-39586213newstex/BW-0001-39586213xmlNewstex Inc.2005Fero Industries, Inc.Newstex Inc.newstex.comnewstexBW-0001-39586213Business Wire0001Business WireBW1Newstex Inc.Business Wire070000000700100004000000040020000400200604016000040160050701400007014012070030000700300113000000130100001301000510 Nov 2009 10:22:20 EST18000000180160001900000019001000190010211900200411/10/2009 Nov. ##, #### (Business Wire) -- Fero Industries, Inc. (OTCBB: FROI) (the “Company”) is pleased to announce to the appointment of Robert C. Moellering, Jr., M.D. as Chairman of the Scientific Advisory Board of Pyro Pharmaceuticals,...BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEFERO INDUSTRIES INC.MERCK & CO INCBMYBMY PRFROIMRKNewsNewstexhttp://www.alacrastore.com/research/moodys-global-credit-research-Bristol_Myers_Squibb_Company-PBC_111270PBC_111270moodys/PBC_111270pdf09 Nov 2009 07:08:06 ESTpdfBristol-Myers Squibb CompanyBristol-Myers Squibb Company115000300.000017 Sep 2008AnalysisAnalysisC...Bristol-Myers Squibb Company's ("Bristol") A# rating reflects a blend of the company's strong competitive position, its significant scale (with revenues of over $## billion), its diverse product pipeline and limited near-term patent expirations. However, these factors are offset by rising challenges, including exposure to one of the most sizeable patent expiration cliffs in the industry approaching in the ####-#### timeframe, limited free cash flow (due to a large shareholder dividend), and an evolving M&A strategy focusing on higher-risk (albeit higher reward) biotechnology products. These factors contributed to Moody's July #### outlook revision to negative from stable. As a result, Bristol's rating is now more sensitive to any unforeseen disappointments (e.g. an unexpected product withdrawals or significant pipeline setbacks). In the backdrop of a more challenging regulatory environment, Bristol will need to successfully advance its late-stage pipeline that already may not be sufficient... 1150001150001828182818291829545545600045912600045912621621656656711000711000711400711400711700711700UNITED STATESUNITED STATESINDUSTRIALINDUSTRIAL115000115000Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39546798BW-0001-39546798newstex/BW-0001-39546798xmlNewstex Inc.2005Albany Molecular Research, Inc.Newstex Inc.newstex.comnewstexBW-0001-39546798Business Wire0001Business WireBW1Newstex Inc.Business Wire0800000008005000040000000401600004016048040160180401600104016013040160030400200004002006070000000701400007014012010000000101000001010001010110000101100601011001010110020101100402000000020020000200200809 Nov 2009 08:24:42 EST1800000018004000180080001801500018022000180200001801800019000000190020001900200711/9/2009 Nov. #, #### (Business Wire) -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the third quarter ended September ##, ####. Financial highlights for the quarter and other significant events include: Recurring...Albany Molecular Research, Inc.BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEAMRIBMYBMY PRNewsNewstexhttp://www.alacrastore.com/storecontent/bir/541809541809bir/541809norm17Bristol-Myers Squibb Co.Acordis Specialty FibresDuPont Chemicals L.P.DuPont PharmaceuticalsDuPont Pharma, Inc.Kosan Biosciences Inc.United States04 Nov 2009 06:22:00 ESTBristol-Myers Squibb Company (BMS) was originally founded and established by two former fraternity brothers, William McLaren Bristol and John Ripley Myers and began trading on the New York Stock Exchange (NYSE) July 5, 1929, later incorporating in the staNYSE325412M2834I5417108731BMYBristol-Myers Squibb Company (BMS) was originally founded and established by two former fraternity brothers, William McLaren Bristol and John Ripley Myers and began trading on the New York Stock Exchange (NYSE) July 5, 1929, later incorporating in the staCompany Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/newstex/BW-0001-39355808BW-0001-39355808newstex/BW-0001-39355808xmlNewstex Inc.2005Albany Molecular Research, Inc.Newstex Inc.newstex.comnewstexBW-0001-39355808Business Wire0001Business WireBW1Newstex Inc.Business Wire040000000400200004002006040160000401601302 Nov 2009 09:36:05 EST18000000180220001801500011/2/2009 Nov. #, #### (Business Wire) -- AMRI (NASDAQ: AMRI) announced today that a third compound being developed under its license and research agreement with Bristol-Myers Squibb Company (NYSE: BMY) will proceed into preclinical development....Albany Molecular Research, Inc.BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEAMRIBMYBMY PRNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B2387860B2387860ccbn/B2387860norm22 Oct 2009 02:07:00 EST2387860Edited Brief of BMY earnings conference call or presentation, 22-Oct-09 10:30am ETBristol-Myers Squibb54.0000EditedBristol-Myers Squibb Q3 2009 Earnings Conference Call SummaryBMY10:30am ETBrief...John Elicker Bristol-Myers Squibb - VP, IR Jim Cornelius Bristol-Myers Squibb - Chairman, CEO Jean-Marc Huet Bristol-Myers Squibb - CFO Elliott Sigal Bristol-Myers Squibb - Chief Scientific Officer Lamberto Andreotti Bristol-Myers Squibb - President... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2387860T2387860ccbn/T2387860norm22 Oct 2009 02:07:00 EST2387860Final Transcript of BMY earnings conference call or presentation, 22-Oct-09 10:30am ETBristol-Myers Squibb54.0000FinalBristol-Myers Squibb Q3 2009 Earnings Conference Call TranscriptBMY10:30am ETTranscript...John Elicker Bristol-Myers Squibb - VP, IR Jim Cornelius Bristol-Myers Squibb - Chairman, CEO Jean-Marc Huet Bristol-Myers Squibb - CFO Elliott Sigal Bristol-Myers Squibb - Chief Scientific Officer Lamberto Andreotti Bristol-Myers Squibb - President... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-39057260BW-0001-39057260newstex/BW-0001-39057260xmlNewstex Inc.2005Bristol-Myers Squibb CompanyNewstex Inc.newstex.comnewstexBW-0001-39057260Business Wire0001Business WireBW1Newstex Inc.Business Wire0700000007005000070130000400000004002000040020060401600004016048040160180401600104016005040160310400600004006005040100000401000107014000070140080701401207014006070140090701401413000000130100001301000502000000020020000200200622 Oct 2009 08:23:41 EST1800000018008000180040001802000018016000180180001900000019002000190020071900200419002013190010001900103510/22/2009 Oct. ##, #### (Business Wire) -- Bristol-Myers Squibb Company (NYSE:BMY) today reported strong sales and earnings growth for the third quarter ####. “The performance in the third quarter of #### clearly shows the results of our outstanding...BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEJAMES M CORNELIUSBMYBMY PRNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-38860048BW-0001-38860048newstex/BW-0001-38860048xmlNewstex Inc.2005Five Prime Therapeutics, Inc.Newstex Inc.newstex.comnewstexBW-0001-38860048Business Wire0001Business WireBW1Newstex Inc.Business Wire0900000009015000070000000700500004000000040020000400200604016000040160010400600004006001070030000700300115 Oct 2009 09:25:33 EST180000001800700010/15/2009 Oct. ##, #### (Business Wire) -- Five Prime Therapeutics, Inc. today announced the appointment of three executives to its management team. Aron Knickerbocker joins as vice president business development , Marc Belsky as vice president...AMGEN INCBRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEAMGNBMYBMY PRNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-38747030BW-0001-38747030newstex/BW-0001-38747030xmlNewstex Inc.2005Phyton Biotech GmbHNewstex Inc.newstex.comnewstexBW-0001-38747030Business Wire0001Business WireBW1Newstex Inc.Business Wire04000000040020000400200104002006040160000401603102000000020020000200200813000000130100001301000512 Oct 2009 04:27:29 EST18000000180180001900000019003000190020001900200710/12/2009 Oct. ##, #### (Business Wire) -- Phyton Biotech GmbH, a world leader in plant cell culture technology, reports that the European Patent Office has announced its intention to grant a European patent to Phyton covering methods of producing...BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEBMYBMY PRNewsNewstex